HC Wainwright & Co.: Maintains buy rating for Leap Therapeutics (LPTX.US) with a target price adjustment from $7.00 to $5.50.
HC Wainwright & Co.：维持Leap Therapeutics(LPTX.US)评级，由买入调整至买入评级, 目标价由7.00美元调整至5.50美元。
HC Wainwright & Co. : Maintaining the Leap Therapeutics (LPTX.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $7.00 to $5.50.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.